

EXPRESS MAIL CERTIFICATE

Date 3/26/01 Label No. 4853597233US


I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Docket No.: 0630/1E791US1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Vedrana S. SUSULIC and Emir DUZIC

Serial No.: 09/761,116

Filed: January 16, 2001

For: TRANSCRIPTIONAL REGULATION OF THE HUMAN BETA 3 -
ADRENERGIC RECEPTOR GENE

March 26, 2001

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449. Copies of the documents listed thereon can be found in the file wrapper of parent application Serial No. 09/243,335, filed February 1, 1999 (see 37 C.F.R. §1.98(d)).


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Docket No. 0630/1D532US1

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Paul F. Fehlner". The signature is written in a cursive style with a horizontal line underneath.

Paul F. Fehlner, Ph.D.
Registration No. 35,135
Attorney for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, NY 10022
(212) 527-7700

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 0630/1E791US1
APPLICANT: Vedrana S. SUSULICSERIAL NO: 09/761,116
FILING DATE: January 16, 2001**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
	*1. 5,789,654	8/1998	Lowell et al	800	2	
	*2. 5,683,912	11/1997	Elgoyhen et al	435	252.3	

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u> <u>YES</u> <u>NO</u>
	*3. WO 94/02590	2/3/94	PCT	C12N	1/21	

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)*****EXAMINER
INITIALS**

*4. Ito et al (1998) Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elements. Diabetes 47:1464-1471.

*5. Wilson et al (1995) C. elegans cosmic F18E9. GenBank accession No. U29614, June 22, 1995, accessed January 15, 2000.

*6. Ohara, et al. " Homo sapiens mRNA for KIAA0537" EMHUM DATABASE ENTRY AB01109, ACCESSION NUMBER AB011109

*7. Razik et al., J. Biol. Chem., 272:28237-28246, 1997

*8. Cohen, et al., The American Society for Biochemistry and Molecular Biology, Inc. 272:2901-2913, 1997

*9. Viñals, et al., The Journal of Biological Chemistry 272:12913-12921, 1997

*10. McPherson et al., PNAS 94:4342-4347, 1997


*11. Strosberg, Ann. Rev. Pharmacol. Toxicol. 37:421-450, 1997

*12. Yoshioka et al., Diabetologia 39: 1410-1411, 1996

*13. Fujisawa et al., Diabetologia 39:349-352, 1996

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO. 0630/1E791US1
APPLICANT: Vedrana S. SUSULICSERIAL NO:
FILING DATE:*EXAMINER
INITIALS

- *15. Zhang et al., Diabetologia 39:1505-1511, 1996
- *16. Wilson et al., The Journal of Pharmacology and Experimental Therapeutics 279:214-221, 1996
- *17. Champigny and Ricquier, J. of Lipid Res., 37:1907-1914, 1996
- *18. Rolland et al., The Journal of Biological Chemistry 271:21297-21302, 1996
- *19. Granneman and Lahners, Endocrinology 135, 1025-1035, 1994
- *20. Largis et al., Drug Dev. Res. 32:69-76, 1994
- *21. Lönnqvist et al. Br. J. Biochem., 110: 929-936, 1993
- *22. Krief et al., J. Clin. Invest. 91:344-349, 1993
- *23. Van Spronsen et al., Eur. J. Biochem. 273:1117-1124, 1993
- *24. Thomas et al., Mol. Pharmacol., 43:343-348, 1993
- *25. Liggett, et al., Mol. Pharmacol., 42:634-637, 1992
- *26. Granneman et al., Mol. Pharmacol. 42:964-970, 1992
- *27. Yamamoto et al., Transcriptional Regulation, Cold Spring Harbor Laboratory Press, 1992, pp. 1169-1192)
- *28. Nahmias, et al., EMBOJ., 10:3721-3727, 1991
- *29. Liggett et al., J. DNA Sequencing and Mapping 2:61-63, 1991
- *30. Thomas and Liggett, Mol. Pharmacol., 43:343-343, 1991
- *31. Muzzin et al., J. Biol Chem. 266:24053-24058, 1991
- *32. Emorine et al., Science 245:1118-1121, 1989
- *33. Dawson et al., The Journal of Biological Chemistry 263:3372-3379, 1988
- *34. Kobilka et al., The Journal of Biological Chemistry 262:7321-7327, 1987
- *35. Cantor et al., Nucl. Acids Res. 12:8059-8072, 1984

*REFERENCES NOT SUPPLIED AS THEY CAN BE FOUND IN FILE WRAPPER OF PARENT APPLN. SERIAL NO. 09/243,335, FILED FEBRUARY 1, 1999.

EXAMINER: _____

DATE CONSIDERED: _____

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.